Quercis Pharma AG is a private Swiss biotech company advancing a novel antithrombotic in multiple indications: the lead program is prevention of Venous Thrombosis Embolism in advanced cancer patients (phase III) followed by clinical trials in Sickle Cell Disease (phase II) and Covid-19 (phase II).

Products, services, technology

Quercis' drug candidate is a an isoquercetin-based formulation that prevents platelet activation and initiation of the thrombotic cascade without increasing the risk of bleeding.

Cooperation possibilities

Quercis is open for licensing partnerships.


Nordstrasse 5, 6300 Zug, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business